Skip to main content
Caplight Logo









Euformatics

Euformatics

Private
EspooHealthcare & Life Scienceshttps://www.euformatics.com/

Last Round

Grant

Jul 1, 2022

Total Funding Raised

$755,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Euformatics is a healthcare technology company that develops and markets bioinformatics software tools for clinical genomic data analysis, quality control, and interpretation for hospitals and clinical laboratories.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Healthcare Analytics, Biotechnology, Quality Management

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Usage-Based SaaS

AI Layer

Application

Keywords

bioinformatics softwaregenomic data interpretationNGS data analysisNGSvariant interpretationNGS quality controlclinical genomicsprecision medicine softwareclinical reportingNGS test validationbioinformatics SaaSIVDR compliancesequencer-agnosticAI in genomics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Euformatics Comparables

Compare Euformatics with similar companies based on industry and business-model similarity.

Euformatics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Limbus Medical Technologies GmbH
85%
Intelliseq
85%
SeqOne
84%

Euformatics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 1, 2022
GrantAug 2, 2021
SeedSep 20, 2016

Key People

Founding team and executive leadership

Jussi Volanen

CTO

Executive Team

Euformatics Investors

Notable investors and investment history

Euformatics investors
InvestorRounds
European CommissionGrant
TekesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 15, 115% of headcount.

  • Nov 10, 2025

    Monthly visitors grew 5228% MoM, reaching 7.1K.

Euformatics Filings

Explore SEC and related filing metadata, where available.

Euformatics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Euformatics's valuation, stock price, and market status.

Is Euformatics a public or private company?

Euformatics is a private company.

What is the current stock price of Euformatics?

Euformatics is a private company with no public stock price. No recent secondary market data is available.

How much is Euformatics worth (valuation)?

Valuation information for Euformatics is not publicly available.

Can I buy Euformatics stock?

Euformatics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Euformatics's last funding round?

Euformatics's most recent funding round was Grant on July 1, 2022.

Who are the main investors in Euformatics?

Key investors in Euformatics include European Commission's Recovery and Resilience Facility, Tekes.

Will Euformatics IPO soon?

No public IPO plans have been announced for Euformatics.

How can I track Euformatics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Euformatics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersEspoo
Employee Range12
Year Founded2010
Last FundingJul 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?